Please login to the form below

Not currently logged in
Email:
Password:

cell cancer

This page shows the latest cell cancer news and features for those working in and with pharma, biotech and healthcare.

Newly-listed BioNTech buys Neon to boost cell therapy assets

Newly-listed BioNTech buys Neon to boost cell therapy assets

BioNTech said the deal would expand its CAR-T and T cell receptor (TCR) pipeline, allowing it to tap into Neon’s portfolio of cancer neoantigens – newly formed antigens that have ... Neon is still conducting follow-up on a second trial of NEO-PV-01

Latest news

More from news
Approximately 1 fully matching, plus 760 partially matching documents found.

Latest Intelligence

  • Cell and gene therapy Cell and gene therapy

    patient.”. Althoff cites Novartis’ Kymriah (tisagenlecleucel), a blood cancer cell therapy approved in Europe and the US last year, as an example of the differing manufacturing costs. ... As a result, Lonza’s efforts to reduce cell and gene therapy

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    It sealed its dominance last year with a string of successful endpoint-hitting trials, most especially in non- small cell lung cancer (NSCLC). ... Keytruda extends its lead. Keytruda established itself as the new standard for first-line treatment of

  • China’s clinical trial shake-up China’s clinical trial shake-up

    For example, around 40% of new lung cancer diagnoses worldwide are in China. ... Once seen as a manufacturer of generics rather than a developer of innovative drugs, China is now involved in half of all enrolling cancer trials of CAR-T cell therapies.

  • Is China ready for a pharmaceutical gold rush?

    Bristol-Myers Squibb’s (BMS)’s Opdivo (nivolumab) was approved for the treatment of non-small cell lung cancer (NSCLC) in June. ... The programmed cell death 1 (PD-1) immune checkpoint inhibitor works by restoring the immune system’s ability to

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    Cancers by their very nature are unique. The huge range of potential causes of the abnormal cell division that characterises cancer mean that every tumour is different. ... Drug development is outpacing our capacity to develop biomarkers due to the

More from intelligence
Approximately 0 fully matching, plus 38 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics